Cancer treatment outcomes have significantly improved over the past decade associated with the discovery and advancement of targeted therapies and immunotherapies.

Recent progress in the understanding of the biology of cancer now permits rational treatment selection significantly improving survival. Keyholder Funding Limited is providing selected investment opportunities in the field of Oncology.

The opportunities are de-risked, asset-based investment in some of the most exciting, disruptive and potentially profitable developments in the fight against cancer. The developments chosen to be in this investment programme are subjected to an extremely rigorous selection process. They are late stage, transitional assets to be taken to commercialisation.

Targeted returns of 8X initial investment.

Target term 18 months.